These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23999886)

  • 1. Expression of vascular endothelial growth factor receptor 2 (VEGFR-2), inducible nitric oxide synthase (iNOS), and Ki-M1P in skull base chordoma: a series of 145 tumors.
    Akhavan-Sigari R; Gaab MR; Rohde V; Brandis A; Tezval H; Abili M; von Eckardstein K; Ostertag H
    Neurosurg Rev; 2014 Jan; 37(1):79-88. PubMed ID: 23999886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma.
    Morimoto Y; Tamura R; Ohara K; Kosugi K; Oishi Y; Kuranari Y; Yoshida K; Toda M
    J Neurooncol; 2019 Aug; 144(1):65-77. PubMed ID: 31240525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of immunohistochemical expression of VEGFR2 and iNOS in spinal chordoma.
    Akhavan-Sigari R; Gaab MR; Rohde V; Abili M; Ostertag H
    Eur Spine J; 2014 Nov; 23(11):2416-22. PubMed ID: 24929808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Connection between expression of inducible nitric oxide synthase (iNOS) in skull base chordoma and lower urinary tract symptoms.
    Akhavan-Sigari R; Ostertag H; Rohde V; Tezval H
    Int Urol Nephrol; 2014 Nov; 46(11):2109-16. PubMed ID: 25113512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.
    Akhavan-Sigari R; Abili M; Gaab MR; Rohde V; Zafar N; Emami P; Ostertag H
    Neurosurg Rev; 2015 Jan; 38(1):89-98; discussion 98-9. PubMed ID: 25323095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chordoma of the skull base: predictors of tumor recurrence.
    Pallini R; Maira G; Pierconti F; Falchetti ML; Alvino E; Cimino-Reale G; Fernandez E; D'Ambrosio E; Larocca LM
    J Neurosurg; 2003 Apr; 98(4):812-22. PubMed ID: 12691407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis.
    Sakai K; Hongo K; Tanaka Y; Nakayama J
    Brain Tumor Pathol; 2007; 24(2):57-62. PubMed ID: 18095132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oedema extension in cerebral metastasis and correlation with the expression of nitric oxide synthase isozymes (NOS I-III).
    Ludwig HC; Ahkavan-Shigari R; Rausch S; Schallock K; Quentin C; Ziegler D; Bockermann V; Markakis E
    Anticancer Res; 2000; 20(1A):305-10. PubMed ID: 10769672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Value of Transforming Growth Factor-α and Ki-67 for the Prognosis of Skull Base Chordoma.
    Zhang S; Bai J; Li M; Zhai Y; Wang S; Liu Q; Li C; Gui S; Zhang Y
    World Neurosurg; 2019 Sep; 129():e199-e206. PubMed ID: 31125781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
    Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
    Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of growth factors and structural proteins in chordomas: basic fibroblast growth factor, transforming growth factor alpha, and fibronectin are correlated with recurrence.
    Deniz ML; Kiliç T; Almaata I; Kurtkaya O; Sav A; Pamir MN
    Neurosurgery; 2002 Sep; 51(3):753-60; discussion 760. PubMed ID: 12188955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
    Luo P; Wang X; Zhou J; Li L; Jing Z
    Hum Pathol; 2018 Apr; 74():129-134. PubMed ID: 29317233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.
    Shalaby A; Presneau N; Ye H; Halai D; Berisha F; Idowu B; Leithner A; Liegl B; Briggs TR; Bacsi K; Kindblom LG; Athanasou N; Amary MF; Hogendoorn PC; Tirabosco R; Flanagan AM
    J Pathol; 2011 Feb; 223(3):336-46. PubMed ID: 21171079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chordoma: Immunohistochemical Analysis of Brachury.
    Sun HI; Guduk M; Gucyetmez B; Yapicier O; Pamir MN
    Turk Neurosurg; 2018; 28(2):174-178. PubMed ID: 28094431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma.
    Huo X; Ma S; Wang C; Song L; Yao B; Zhu S; Li P; Wang L; Wu Z; Wang K
    Clin Transl Med; 2023 Oct; 13(10):e1429. PubMed ID: 37784253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intradural chordoma of the Meckel's cave: a challenging differential diagnosis.
    Barresi V; Caffo M; Alafaci C; Granata F; Tuccari G
    Neuropathology; 2012 Oct; 32(5):577-82. PubMed ID: 22260529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of nitric oxide synthase isozymes (NOS I-III) by immunohistochemistry and DNA in situ hybridization. Correlation with macrophage presence, vascular endothelial growth factor (VEGF) and oedema volumetric data in 220 glioblastomas.
    Ludwig HC; Feiz-Erfan I; Bockermann V; Behnke-Mursch J; Schallock K; Markakis E
    Anticancer Res; 2000; 20(1A):299-304. PubMed ID: 10769671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas.
    Horbinski C; Oakley GJ; Cieply K; Mantha GS; Nikiforova MN; Dacic S; Seethala RR
    Arch Pathol Lab Med; 2010 Aug; 134(8):1170-6. PubMed ID: 20670138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fascin expression in skull base chordoma: correlation with tumor recurrence and dura erosion.
    Gao Z; Zhang Q; Kong F; Chen G; Li M; Guo H; Liang J; Bao Y; Ling F
    Med Oncol; 2012 Dec; 29(4):2438-44. PubMed ID: 22351250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.